These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 33206479)

  • 1. [New developments in systemic sclerosis-associated interstitial lung disease].
    Humair G; Daccord C; Beigelman-Aubry C; Lazor R
    Rev Med Suisse; 2020 Nov; 16(715):2218-2223. PubMed ID: 33206479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic sclerosis-associated interstitial lung disease.
    Perelas A; Silver RM; Arrossi AV; Highland KB
    Lancet Respir Med; 2020 Mar; 8(3):304-320. PubMed ID: 32113575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial lung disease in systemic sclerosis.
    Bussone G; Mouthon L
    Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
    Yamasaki Y; Kuwana M
    Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review.
    Tan A; Denton CP; Mikhailidis DP; Seifalian AM
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S66-74. PubMed ID: 21586221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Systemic sclerosis-related interstitial lung disease: Diagnostic and therapeutic strategy in the light of recent clinical trials].
    Lescoat A; Jouneau S; Uzunhan Y; Jégo P; Cottin V; Hachulla E
    Rev Med Interne; 2022 Jun; 43(6):365-374. PubMed ID: 35181160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Sclerosis and Pulmonary Disease.
    Ngo K
    Adv Exp Med Biol; 2021; 1303():173-182. PubMed ID: 33788193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
    Volkmann ER; Tashkin DP
    Ann Am Thorac Soc; 2016 Nov; 13(11):2045-2056. PubMed ID: 27560196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interstitial lung disease in systemic sclerosis].
    Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
    Presse Med; 2006 Dec; 35(12 Pt 2):1943-51. PubMed ID: 17159721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?
    Iudici M; Moroncini G; Cipriani P; Giacomelli R; Gabrielli A; Valentini G
    Autoimmun Rev; 2015 Jul; 14(7):575-8. PubMed ID: 25709096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis.
    Aringer M; Riemekasten G
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101672. PubMed ID: 33745826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Connective tissue disease-related interstitial lung disease].
    Lefeuvre L; Dan D
    Rev Med Suisse; 2021 Mar; 17(729):492-496. PubMed ID: 33689246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [How do I treat interstitial lung disease in systemic sclerosis?].
    Riemekasten G
    Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease as the first manifestation of systemic sclerosis.
    van der Kamp R; Tak PP; Jansen HM; Bresser P
    Neth J Med; 2007 Nov; 65(10):390-4. PubMed ID: 18057462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of fibrosing diffuse parenchymal lung disease.
    Morgenthau AS; Padilla ML
    Mt Sinai J Med; 2009 Feb; 76(1):2-23. PubMed ID: 19170214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial lung disease in scleroderma.
    Schoenfeld SR; Castelino FV
    Rheum Dis Clin North Am; 2015 May; 41(2):237-48. PubMed ID: 25836640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interstitial lung disease in systemic sclerosis: current and future treatment.
    Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
    Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?
    Herzog EL; Mathur A; Tager AM; Feghali-Bostwick C; Schneider F; Varga J
    Arthritis Rheumatol; 2014 Aug; 66(8):1967-78. PubMed ID: 24838199
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic sclerosis-associated interstitial lung disease.
    Scallan CJ; Collins BF; Raghu G
    Curr Opin Pulm Med; 2020 Sep; 26(5):487-495. PubMed ID: 32740379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.